Home
NewsNewsINVO Fertility would be introducing time-lapse incubation technology at its Wisconsin clinic, hence offering high-quality lab care, creative patient solutions, and advanced embryo monitoring for improved fertility results.
INVO Fertility, Inc., a healthcare services fertility company that helps people get advanced reproductive treatment by setting up, acquiring as well as running fertility clinics along with related businesses and technologies, on March 5, 2026, went ahead and announced that its Wisconsin clinic would start using time-lapse incubation technology. This integration shows that INVO is indeed dedicated to providing modern, high-quality lab care and creative patient solutions, as well as to improving the quality of labs and clinics across its growing network.
According to COO of INVO, April McGhee, “INVO Fertility is proud to introduce this time-lapse incubation technology as part of our ongoing focus on quality and innovation and the expansion of additional patient service offerings. This technology enhances the tools available to our embryology teams while aligning with our commitment to delivering thoughtful, patient-centred fertility care.”
INVO is looking out to improve its clinics and help its clinical and laboratory teams and also throttle its mission of providing accessible, patient-centred fertility care by using proven new ideas like time-lapse incubation. This adoption shows that the company is keeping its promise to invest in cutting-edge technologies that improve the treatment journey for patients. It is also part of the company's larger plan to responsibly integrate cutting-edge reproductive technologies that provide real value to patients and doctors.
Remarks CEO Steve Shum, “Our approach to innovation is intentional. We focus on technologies that may enhance quality and outcomes while staying true to our mission of expanding access to fertility care through continuous, responsible innovation.”
ARMS Embryo Watch offers time-lapse images of IVF embryos to patients by streaming each development stage and showing the output directly to the patient's device, enhancing transparency and emotional connection throughout the IVF journey.
Mochida Grants LG Chem Endometriosis Drug Licensing to develop and sell Dinagest that has an active ingredient, Dienogest, that halts endometrial cells from growing, offering a non-hormonal therapeutic option for women suffering from endometriosis.
Luna and Kindbody are redefining Intelligence in Fertility Care through a strategic partnership that integrates wearable biomarker tracking into clinical pathways. By capturing real-time physiological data, the collaboration enables personalised insights, enhances decision-making, and creates a more connected, data-driven fertility journey for patients and care providers alike.
The MOAA-Endorsed Bill for Fertility Challenges seeks to expand fertility care access for veterans by recognising infertility as a service-connected condition. By reducing barriers to IVF and treatment, the legislation addresses toxic exposure risks and aims to provide timely, equitable reproductive healthcare support for those who served.
Fairfax IVI expand donor sperm access through a strategic partnership that enhances availability, integrates donor services into fertility care, and supports diverse patient needs. With personalised guidance, genetic insights, and streamlined logistics, the collaboration aims to reduce barriers and deliver a more accessible, inclusive path to parenthood.
Sapyen and Avenues launch at-home fertility diagnostics, introducing a couple-first testing model in the UK. By integrating semen analysis and AMH testing into early care, this approach reduces clinic visits, accelerates diagnosis, and ensures balanced fertility evaluation, transforming how patients begin their reproductive health journey.
Nexpring Health has invested in May Health to accelerate the development of the Anavi™ System, a novel device designed to treat PCOS-Related Infertility. The technology aims to restore ovulation through a single office-based procedure, expanding treatment options for millions of women affected by polycystic ovary syndrome.
